ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1749

Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis

Eddie James1, Cliff Rims2, Sylvia Posso2, Jeffrey Carlin3, William Kwok2, Shao-En Ong4 and Jane Buckner1, 1Benaroya Research Institute at Virginia Mason, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3Virginia Mason Medical Center, Seattle, WA, 4University of Washington, Seattle, WA

Meeting: ACR Convergence 2022

Keywords: autoantigens, immunology, rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease in which citrullinated self-antigens are recognized by anti-citrullinated protein antibodies (ACPA) and T cells. ACPA are a key diagnostic indicator of disease and have been shown to bind to arrays of citrullinated self-proteins that are expressed in synovial tissue. To date, the majority of T cell studies have focused on well-documented ACPA targets. Although considerable antigenic overlap between self-reactive CD4+ T cells and antibodies can be reasonably anticipated, T cell targets that are not known to be targeted by ACPA are likely to comprise an important (but as yet, understudied) component of the antigen specific responses that underlie disease. Furthermore, although CD8+ T cells comprise a significant proportion of T cells within synovial tissue and fluid, knowledge about their specificity remains extremely limited. Therefore, we sought to generate relevant HLA peptidomics data sets to inform T cell antigen discovery efforts.

Methods: To characterize the disease proximal HLA peptidome, synovial tissue was obtained from 7 subjects with seropositive RA and 4 subjects with seronegative RA who had undergone arthroplasty procedures. Synovial cells were isolated from tissue after mincing and digesting in collagenase I. After confirming HLA expression by flow cytometry, samples were solubilized in lysis buffer and human leukocyte antigen (HLA) class I and HLA-DR complexes were captured (separately) on affinity columns. HLA-Class I- or HLA-DR-bound peptides were eluted in acetic acid, concentrated, and peptide spectra were identified by LC-MS/MS analysis. The resulting datasets were assigned sequences by searching against a human protein database. Mass shifts associated with each assigned sequence were utilized to identify post-translational modifications – most notably citrullination of native arginine residues. Comprehensive libraries of the HLA-Class I- and HLA-DR-bound peptides from each individual were imported into a custom database, which was then used to catalogue the most prevalent self-proteins for each patient type.

Results: The most prevalent self-proteins in the HLA-DR-bound peptidome from the synovial tissue of RA subjects included expected targets such as vimentin, alpha-enolase, fibrinogen, collagen, histones, and BIP but also contained more novel targets such as fibronectin, gelsolin, and proteoglycan 4. Prevalent self-proteins in the HLA-Class I-bound peptidome included well-studied CD4+ T cell targets such as vimentin, alpha-enolase, and collagen but also contained more novel targets such as caspase-14, stromelysin-1, and filamin-A. Among these candidates, we focused on gelsolin as a putative antigen, identifying multiple peptides with apparent T cell immunogenicity.

Conclusion: These findings demonstrate that HLA peptidomic analysis of synovial tissue provides a rich source of candidate antigens for T cell studies. Assessing T cell responses toward such novel antigens has the potential to provide important new insights about the specificity and character of antigen specific T cell responses that promote the development of RA.


Disclosures: E. James, Janssen, Provention Bio, Bristol-Myers Squibb(BMS), Novartis; C. Rims, None; S. Posso, None; J. Carlin, None; W. Kwok, None; S. Ong, None; J. Buckner, Amgen, Bristol Myers Squibb, Gentiobio, Hot Spot Therapeutics, Janssen, Pfizer, Novo Nordisk, Allen Institute for Immunology, Type 1 Diabetes TrialNet Study Group, La Jolla Institute, Oklahoma Medical Research Foundation, Bristol Myers Squibb Immunology, Colton Center for Autoimmunity at Penn, Board of Scientific Counsellors.

To cite this abstract in AMA style:

James E, Rims C, Posso S, Carlin J, Kwok W, Ong S, Buckner J. Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/mass-spectrometry-based-hla-peptidomics-analysis-reveals-both-expected-and-novel-citrullinated-antigen-targets-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mass-spectrometry-based-hla-peptidomics-analysis-reveals-both-expected-and-novel-citrullinated-antigen-targets-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology